Suchergebnisse - "Brito, Dulce"

PubPharm (20)

1

Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease : The Beta3-LVH Phase 2b Randomized Clinical Trial

enthalten in: JAMA cardiology | 2023

von Balligand, J. | Brito, D. | Brosteanu, O. | +25

2

The value of multiparametric prediction scores in heart failure varies with the type of follow-up after discharge : a comparative analysis

enthalten in: ESC heart failure | 2023

von Rodrigues, T. | Agostinho, J. | Santos, R. | +10

3

World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

enthalten in: Global heart | 2023

von Brito, D. | Albrecht, F. | de Arenaza, D. | +16

4

Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry

enthalten in: European heart journal. Quality of care & clinical outcomes | 2022

von Lopes, L. | Losi, M. | Sheikh, N. | +119

5

Management of RAASi-associated hyperkalemia in patients with cardiovascular disease

enthalten in: Heart failure reviews | 2021

von Silva-Cardoso, J. | Brito, D. | Frazão, J. | +4

6

Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy

enthalten in: European journal of heart failure | 2021

von Garcia-Pavia, P. | Bengel, F. | Brito, D. | +8

7

NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction : TRANSITION Study

enthalten in: JACC. Heart failure | 2020

von Pascual-Figal, D. | Wachter, R. | Senni, M. | +106

8

Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy

enthalten in: Heart (British Cardiac Society) | 2020

von Bégué, C. | Mörner, S. | Brito, D. | +12

9

Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge : primary results of the randomised TRANSITION study

enthalten in: European journal of heart failure | 2019

von Wachter, R. | Senni, M. | Belohlavek, J. | +123

CommentIn: Eur J Heart Fail. 2019 Aug;21(8):1008-1011. - PMID 31218805

10

Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH)

enthalten in: ESC heart failure | 2018

von Pouleur, A. | Anker, S. | Brito, D. | +22

ErratumIn: ESC Heart Fail. 2018 Dec;5(6):1199. - PMID 30570224